Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE)
Latest Information Update: 14 Jul 2022
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms IRENE
- Sponsors Eisai Co Ltd
- 12 Jul 2022 Status changed from active, no longer recruiting to completed.
- 10 Mar 2022 Planned End Date changed from 1 Apr 2022 to 30 Apr 2022.
- 10 Mar 2022 Planned primary completion date changed from 1 Apr 2022 to 30 Apr 2022.